Potential EU drug voucher scheme criticized - "a random group of patients will foot the bill"
The EU is attempting to use a transferable voucher to entice companies to develop new antibiotics. However, this could be expensive for patients, critics say.
The issues surrounding antimicrobial resistance (AMR) are by now very well known.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
